Strategies for continued successful treatment of Alzheimer's disease

Switching cholinesterase inhibitors

Serge Gauthier, Murat Emre, Martin Farlow, Roger Bullock, George T. Grossberg, Steven G. Potkin

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Cholinesterase (ChE) inhibitors represent the standard therapeutic approach to the treatment of Alzheimer's disease (AD). However, a proportion of patients experience lack or loss of therapeutic benefit with an initial agent, or discontinue due to safety/tolerabliity issues, in many instances, no alternative treatment is offered once the initial agent has been stopped. Thus, for many patients, the total duration of treatment is relatively short in comparison with the chronic nature of AD. Switching medications is a common therapeutic strategy within many drug classes across many clinical areas following a lack/loss of efficacy or safety/tolerability problems, and is also an increasingly important concept in the management of AD with ChE Inhibitors. A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [ACHE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). In these studies, rivastigmine was well tolerated, and the occurrence of safety/tolerability problems with donepezil was not predictive of similar problems with rivastigmine. In the summer of 2002, leading neurologists and psychiatrists attended a medical experts meeting to discuss the clinical importance of switching ChE inhibitors in AD. The expert panel examined available clinical data, shared clinical experiences, and discussed current clinical guidelines for switching. The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review.

Original languageEnglish
Pages (from-to)707-714
Number of pages8
JournalCurrent Medical Research and Opinion
Volume19
Issue number8
DOIs
StatePublished - 2003

Fingerprint

Rivastigmine
Cholinesterase Inhibitors
Alzheimer Disease
Safety
Therapeutics
Butyrylcholinesterase
Psychiatry
Consensus
Guidelines
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Guidelines
  • Switching

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Strategies for continued successful treatment of Alzheimer's disease : Switching cholinesterase inhibitors. / Gauthier, Serge; Emre, Murat; Farlow, Martin; Bullock, Roger; Grossberg, George T.; Potkin, Steven G.

In: Current Medical Research and Opinion, Vol. 19, No. 8, 2003, p. 707-714.

Research output: Contribution to journalArticle

Gauthier, Serge ; Emre, Murat ; Farlow, Martin ; Bullock, Roger ; Grossberg, George T. ; Potkin, Steven G. / Strategies for continued successful treatment of Alzheimer's disease : Switching cholinesterase inhibitors. In: Current Medical Research and Opinion. 2003 ; Vol. 19, No. 8. pp. 707-714.
@article{41398ddc58154b3989c7e10608385493,
title = "Strategies for continued successful treatment of Alzheimer's disease: Switching cholinesterase inhibitors",
abstract = "Cholinesterase (ChE) inhibitors represent the standard therapeutic approach to the treatment of Alzheimer's disease (AD). However, a proportion of patients experience lack or loss of therapeutic benefit with an initial agent, or discontinue due to safety/tolerabliity issues, in many instances, no alternative treatment is offered once the initial agent has been stopped. Thus, for many patients, the total duration of treatment is relatively short in comparison with the chronic nature of AD. Switching medications is a common therapeutic strategy within many drug classes across many clinical areas following a lack/loss of efficacy or safety/tolerability problems, and is also an increasingly important concept in the management of AD with ChE Inhibitors. A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50{\%} of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [ACHE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). In these studies, rivastigmine was well tolerated, and the occurrence of safety/tolerability problems with donepezil was not predictive of similar problems with rivastigmine. In the summer of 2002, leading neurologists and psychiatrists attended a medical experts meeting to discuss the clinical importance of switching ChE inhibitors in AD. The expert panel examined available clinical data, shared clinical experiences, and discussed current clinical guidelines for switching. The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review.",
keywords = "Alzheimer's disease, Cholinesterase inhibitors, Guidelines, Switching",
author = "Serge Gauthier and Murat Emre and Martin Farlow and Roger Bullock and Grossberg, {George T.} and Potkin, {Steven G.}",
year = "2003",
doi = "10.1185/030079903125002450",
language = "English",
volume = "19",
pages = "707--714",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Strategies for continued successful treatment of Alzheimer's disease

T2 - Switching cholinesterase inhibitors

AU - Gauthier, Serge

AU - Emre, Murat

AU - Farlow, Martin

AU - Bullock, Roger

AU - Grossberg, George T.

AU - Potkin, Steven G.

PY - 2003

Y1 - 2003

N2 - Cholinesterase (ChE) inhibitors represent the standard therapeutic approach to the treatment of Alzheimer's disease (AD). However, a proportion of patients experience lack or loss of therapeutic benefit with an initial agent, or discontinue due to safety/tolerabliity issues, in many instances, no alternative treatment is offered once the initial agent has been stopped. Thus, for many patients, the total duration of treatment is relatively short in comparison with the chronic nature of AD. Switching medications is a common therapeutic strategy within many drug classes across many clinical areas following a lack/loss of efficacy or safety/tolerability problems, and is also an increasingly important concept in the management of AD with ChE Inhibitors. A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [ACHE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). In these studies, rivastigmine was well tolerated, and the occurrence of safety/tolerability problems with donepezil was not predictive of similar problems with rivastigmine. In the summer of 2002, leading neurologists and psychiatrists attended a medical experts meeting to discuss the clinical importance of switching ChE inhibitors in AD. The expert panel examined available clinical data, shared clinical experiences, and discussed current clinical guidelines for switching. The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review.

AB - Cholinesterase (ChE) inhibitors represent the standard therapeutic approach to the treatment of Alzheimer's disease (AD). However, a proportion of patients experience lack or loss of therapeutic benefit with an initial agent, or discontinue due to safety/tolerabliity issues, in many instances, no alternative treatment is offered once the initial agent has been stopped. Thus, for many patients, the total duration of treatment is relatively short in comparison with the chronic nature of AD. Switching medications is a common therapeutic strategy within many drug classes across many clinical areas following a lack/loss of efficacy or safety/tolerability problems, and is also an increasingly important concept in the management of AD with ChE Inhibitors. A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [ACHE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). In these studies, rivastigmine was well tolerated, and the occurrence of safety/tolerability problems with donepezil was not predictive of similar problems with rivastigmine. In the summer of 2002, leading neurologists and psychiatrists attended a medical experts meeting to discuss the clinical importance of switching ChE inhibitors in AD. The expert panel examined available clinical data, shared clinical experiences, and discussed current clinical guidelines for switching. The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review.

KW - Alzheimer's disease

KW - Cholinesterase inhibitors

KW - Guidelines

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=0345276668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345276668&partnerID=8YFLogxK

U2 - 10.1185/030079903125002450

DO - 10.1185/030079903125002450

M3 - Article

VL - 19

SP - 707

EP - 714

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 8

ER -